Lisanti Capital Growth LLC Sells 38,275 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Lisanti Capital Growth LLC trimmed its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 38.6% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 60,965 shares of the company's stock after selling 38,275 shares during the period. PROCEPT BioRobotics accounts for approximately 1.2% of Lisanti Capital Growth LLC's portfolio, making the stock its 28th largest position. Lisanti Capital Growth LLC owned about 0.12% of PROCEPT BioRobotics worth $4,885,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Values First Advisors Inc. acquired a new position in PROCEPT BioRobotics during the third quarter worth about $27,000. Mark Sheptoff Financial Planning LLC purchased a new position in shares of PROCEPT BioRobotics during the 2nd quarter worth $36,000. Quest Partners LLC lifted its position in PROCEPT BioRobotics by 2,492.3% during the second quarter. Quest Partners LLC now owns 674 shares of the company's stock worth $41,000 after buying an additional 648 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of PROCEPT BioRobotics by 178.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company's stock valued at $89,000 after acquiring an additional 713 shares during the last quarter. Finally, Sentry Investment Management LLC acquired a new stake in shares of PROCEPT BioRobotics in the third quarter worth approximately $120,000. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Wells Fargo & Company boosted their target price on PROCEPT BioRobotics from $67.00 to $69.00 and gave the stock an "overweight" rating in a report on Friday, August 2nd. Piper Sandler reiterated an "overweight" rating and set a $75.00 target price on shares of PROCEPT BioRobotics in a research note on Tuesday, October 8th. Bank of America lifted their target price on PROCEPT BioRobotics from $80.00 to $94.00 and gave the company a "buy" rating in a research note on Thursday, August 22nd. Truist Financial restated a "buy" rating and issued a $105.00 price target (up previously from $95.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, October 30th. Finally, TD Cowen boosted their target price on PROCEPT BioRobotics from $75.00 to $99.00 and gave the stock a "buy" rating in a report on Monday, September 16th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $88.40.

PROCEPT BioRobotics Stock Down 2.3 %

PRCT stock traded down $2.25 during mid-day trading on Monday, hitting $96.82. The stock had a trading volume of 810,875 shares, compared to its average volume of 658,134. The stock has a market capitalization of $5.05 billion, a price-to-earnings ratio of -50.57 and a beta of 1.01. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a 1-year low of $30.83 and a 1-year high of $103.81. The company has a fifty day moving average of $79.43 and a 200 day moving average of $70.19.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its earnings results on Monday, October 28th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.09. The company had revenue of $58.40 million during the quarter, compared to the consensus estimate of $53.30 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The company's revenue for the quarter was up 66.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.51) earnings per share. On average, equities analysts expect that PROCEPT BioRobotics Co. will post -1.74 EPS for the current fiscal year.

Insider Buying and Selling at PROCEPT BioRobotics

In other news, CEO Reza Zadno sold 288,461 shares of the firm's stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $91.00, for a total value of $26,249,951.00. Following the sale, the chief executive officer now owns 258,445 shares in the company, valued at approximately $23,518,495. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Director Antal Rohit Desai sold 34,000 shares of PROCEPT BioRobotics stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $95.39, for a total value of $3,243,260.00. Following the completion of the sale, the director now directly owns 164,363 shares in the company, valued at $15,678,586.57. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Reza Zadno sold 288,461 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $91.00, for a total transaction of $26,249,951.00. Following the completion of the sale, the chief executive officer now owns 258,445 shares in the company, valued at $23,518,495. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 535,353 shares of company stock worth $46,627,426 over the last ninety days. Company insiders own 17.40% of the company's stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).